ALK+ NSCLC
Advertisement
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
Despite decades of decline, "lung cancer continues to dwarf other cancers in the number of deaths," officials said.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Dr. Manochakian discusses the implications of recent phase 3 trials in lung cancer.
Dr. Manochakian discusses the most pressing unanswered questions in lung cancer and how they could be addressed.
Dr. Manochakian shared his insights during the Oncology Brothers Advancements in Oncology event.
Dr. Manochakian discusses new data and why next-generation sequencing is a critical step when treating NSCLC.
The median PFS of patients receiving lorlatinib in the phase 3 CROWN study has yet to be reached with 5 years of follow-up.
The approval is based on results from the phase 3 ALINA study.
Cancer organoid-based drug sensitivity tests have recently been investigated to predict responses to anticancer drugs.
Worse clinical outcomes and higher risk for brain metastasis are more likely to happen in patients with metastatic NSCLC.
Patients of Hispanic/Latino ethnicity have a greater prevalence of certain lung cancer driver mutations.
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.